OBJECTIVES: Chronic immune thrombocytopenia (ITP) is characterized by low platelet counts and an increased risk of bleeding-related episodes (BRE). The study purpose was to estimate the cost of BREs in the US. METHODS: A BRE includes rescue medication use, a bleeding event, or both. The BRE endpoint was tested in two 6-month placebo-controlled trials for romiplostim in adult patients with ITP (median baseline platelet counts of 16 x 10 9 /L; 64% received ≥3 treatments prior to baseline). Results from pooled analyses across studies and treatment arms showed that 63% of BREs were mild (outpatient management without immunoglobulins), 31% were moderate (outpatient management with immunoglobulins), and 6% were severe (inpatient management with immunoglobulins). The annual BRE rate per patient was 1.80 for patients with platelets ≥50 x 10 9 /L at the time of BRE and 7.33 for patients with platelets <50 x 10 9 /L. BRE costs were estimated using 2012 Medicare rates for office visits, oral steroids, immunoglobulins (IVIg dose of 2 g/kg per episode, and Anti-D dose of 50 mcg/kg in 25% of non-splenectomized patients), and hospitalization for intracranial hemorrhage, gastrointestinal hemorrhage, and coagulation disorders. RESULTS: The estimated costs of a mild, moderate, and severe BRE OBJECTIVES: Systemic Lupus Erythematosus(SLE) is a debilitating illness caused by an autoimmune disorder that can affect many organs of the body, including skin, joints, kidneys, lungs and the nervous system. Therapy with steroids and immunosuppressives can lead to further organ damage. Belimumab is a fully human monoclonal antibody that has been found to be effective against SLE in trials. The current study assesses the cost-effectiveness of belimumab in Hong
PSY37 COST IMPACT OF DEPOFOAM BUPIVACAINE FOR THE MANAGEMENT OF POST-SURGICAL PAIN
Ektare V 1 , Scranton R 2 , Botteman MF 1 1 Pharmerit International, Bethesda, MD, USA, 2 Pacira Pharmaceuticals, Parsippany, NJ, USA OBJECTIVES: Clinical trials in soft tissue surgery with Depofoam® bupivacaine (DB) have shown that a single injection into the surgical site provides postsurgical pain control for up to 72 hours while reducing the need for opioids. This study extrapolates via a simplified decision tree the economic impact of DB versus bupivacaine HCl (BH) in patients undergoing colectomy and cholecystectomy. METHODS: This simple model combined data from a claims database analysis with literature. The incidence of opioid use (92%) and risk of ICD-9 diagnosis-coded opioid-related adverse events (ORAEs) (16.32%) for the BH group were estimated via retrospective analysis of the Premier hospital database. The incidence rates of opioid use (68%) and ORAEs (1.86%) in the DB group were based on the relative reduction between DB and BH observed in a hemorrhoidectomy trial. The excess cost per patient with ORAE ($4,707) was estimated from Premier. DB and BH drug acquisition costs, opioid costs (including inpatient pharmacy, administration, errors and outpatient pharmacy) were literature based. Analyses were conducted in 378 subgroups defined by surgery types (colectomy and cholecystectomy) and demographics. RESULTS: Compared to BH, the use of DB is projected to result in an increase in analgesia drug acquisition cost of $249/patient. This was offset by expected reductions in opioids (-$95/patient) and ORAE (-$680/patient) costs, resulting in net cost savings of $526/patient overall. DB resulted in modeled costs savings in all but one of the 378 subgroups. These ranged from cost savings of $1,633/patient in the "open cholecystectomy/admission source trauma" subgroup to a cost increase of $28/patient in the "cholecystectomy/age 18-30" subgroup. CONCLUSIONS: As a result of better pain management and reduced opioids usage, the use of DB (v. BH) at the time of colectomy/cholecystectomy is modeled to be cost saving overall and in 99.7% of subgroups considered.
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FIRST-LINE USE OF CALCIPOTRIENE/BETAMETHASONE DIPROPIONATE COMBINATION PRODUCTS FOR THE TREATMENT OF PLAQUE PSORIASIS IS ASSOCIATED WITH LOWER HEALTH CARE UTILIZATION AND COST
Feldman SR 1 , Levi E 2 , Pathak P 3 , Kakatkar S 3 , Blakrishnan R 4 1 Wake Forest University, Winston-Salem, NC, USA, 2 LEO Pharma Inc., Parsippany, NJ, USA, 3 Outcomes Inc., Dulles, VA, USA, 4 University of Michigan and Outcomes Inc., Dulles, VA, USA OBJECTIVES: Calcipotriene/betamethasone dipropionate combination topical products are an established treatment for patients with plaque psoriasis. In appropriate patients, using the combination products as first-line therapy after the psoriasis diagnosis might be beneficial. This study investigated whether such use might lower the cost impact on health care budgets. METHODS: A retrospective study using Thomson Reuters MarketScan ® national claims data from 2006-2011 was performed to identify patients who received psoriasis medications following a psoriasis diagnosis (ICD-9 code 696.1x). Patients were continuously enrolled during 1-year pre-and post-index date periods. The 2 study cohorts were cohort A (patients treated with calcipotriene/betamethasone dipropionate combination products immediately post-diagnosis) and cohort B (patients treated with any other topical psoriasis medication immediately postdiagnosis). The frequency of office visits and total health care costs (includes pharmacy costs and costs of inpatient and outpatient services) during the 1-year post-index period were assessed. Multiple regression analyses adjusting for baseline demographic and clinical covariates, including a proxy for psoriasis severity, were performed. RESULTS: In total, 16,977 patients were identified in the 2 cohorts based on the topical medication prescribed (cohort A = 7307; cohort B = 9670). During the 1-year follow-up period, mean (± SD) total and psoriasisrelated office visits were significantly lower in cohort A (13.36 ± 14.39; 2.79 ± 7.60) than cohort B (16.08 ± 16.68; 4.25 ± 10.23) (both P<.001). Mean total health care costs were less for cohort A ($7785.80 ± $15,255.60; median = $3411) than cohort B ($11,757.20 ± $19,747.60 ; median = $5595.80) (P<.001). In a generalized linear model adjusted for baseline covariates, cohort A had significantly lower costs than cohort B (β ± SE = 0.041 ± 0.017; P=.02). CONCLUSIONS: First-line treatment with calcipotriene/betamethasone dipropionate combination products after psoriasis diagnosis was associated with fewer office visits and lower total health care costs. 
PSY40 EXPENDITURE AND EFFECTIVENESS OF TREATMENT OPTIONS IN CHRONIC MYELOID LEUKEMIA PATIENTS WHO FAILED IN THE FIRST-LINE IMATINIB TREATMENT
Chen W 1 , Zhu JJ 2 1 Fudan University, Shanghai, China, 2 School of Public Health, Fudan University, Shanghai, China OBJECTIVES: To compare medical expenditure and effectiveness of different therapies in chronic myeloid leukemia patients who failed in the first-line imatinib treatment. METHODS: A structured questionnaire was designed to collect the detailed data from 28 clinical experts, including treatment alternatives for the patients with chronic myeloid leukemia who failed in firstline imatinib treatment, and medical service utilization, medical expenditure and effectiveness of different therapies (nilotinib, imatinib dose-escalation and allo-SCT). RESULTS: The choices of the second-line therapies for the patients who failed in the first-line imatinib treatment included nilotinib, imatinib doseescalation and allo-SCT. The cytogenetic response of nilotinib was always higher than imatinib dose escalation. After 1-1.5 years, the cumulative cytogenetic response rate of nilotinib could be as high as 80%, which is significantly higher than that of imatinib. The most common adverse effects of nilotinib included hematologic toxicities (anemia, thrombocytopenia and neutropenia), hyperbilirubinemia, prolongation of QT interval, liver injuries, skin alterations, edema, jaundice and gastrointestinal disturbance. In parallel, bone marrow suppression is the most frequent toxicities of imatinib dose escalation treatment. Other non-hematologic adverse effects were similar, included fluid retention, gastrointestinal disturbance, muscular cramp and bone and joint pain. The expenditure of nilotinib and dose-escalated imatinib therapies was quite similar, and significantly higher than that of first-line imatinib treatment. CONCLUSIONS: It is strongly suggested that nilotinib treatment should be considered as standard treatment of imatinib-failed patients in China.
PSY41 ESTIMATING THE COST-EFFECTIVENESS OF BELIMUMAB VERSUS STANDARD CARE FOR SLE PATIENTS IN HONG KONG
